On May 21, 2024 U.S. Precision Medicine, Inc. (USPM), a biopharma company developing novel cancer therapeutics, reported it will use state-of-the-art artificial intelligence (AI) technology to bolster independent research that has proven the company’s small molecule candidate is highly effective in killing breast cancer (Press release, US Precision Medicine, MAY 21, 2024, View Source [SID1234643517]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

U.S. Precision Medicine’s new cancer drug candidate has demonstrated the ability to reduce tumor weight and volume by 85% in just 30 days of treatment with no toxicity. The findings were corroborated in the independent Investigational New Drug (IND) research with small animal studies required by the FDA. The company’s contract research organization currently is developing the dosing plan and expanding the research to include an additional 100 cancer types, for which patents or patents pending are held.

"Now that the validity of AI in pharmaceutical drug development is gaining traction, we plan to conduct a comparative study leveraging AI platforms in parallel with our ongoing IND research to prepare for human clinical trials," said Frederick Fey, co-founder and CEO of USPM.

"The drug candidate shows great promise as a treatment for most, if not all, solid tumor cancers, which account for approximately 90 percent of adult cancers and 30 percent of all pediatric cancers."

The worldwide incidence of cancer continues to rise, with the American Cancer Society projecting a 77% increase in new cases by 2050 versus 2022 levels. Last year, there were approximately 20 million new cancer diagnoses and 9.7 million cancer deaths globally.

"Cancer represents a tremendous unmet medical need that is projected to reach $200 billion by 2025 for cancer drugs alone," said Christopher Fey, co-founder and COO of USPM. "My brother and I are passionate about turning cancer victims into survivors because our father passed away from colon cancer at age 29 when we were toddlers. We hope others will join us in improving outcomes for patients across all cancer types."